Загрузка...
Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...
Сохранить в:
| Опубликовано в: : | Clin Lung Cancer |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/ https://ncbi.nlm.nih.gov/pubmed/25922291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|